CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 150 target
Drug / intervention
esketamine group +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06896994
NCT06896994N/ARecruitingMonitorUpdated 14mo ago · Completion was 3mo ago
Slow Enrollment
Monitor
CompareCT.gov

Intravenous Infusion of Esketamine in Combination With Pregabalin and Duloxetine for Postherpetic Neuralgia

Beijing Tiantan Hospital·interventional·Posted Mar 26, 2025·Updated Apr 27, 2025

In Brief

A clinical study evaluating esketamine group and control group for Postherpetic Neuralgia. Currently recruiting, targeting 150 participants across 1 site.

Signals

Enrolling slower than its timeline implies

Detailed Summary

To assess the 1-week effects and safety of esketamine in combination with pregabalin and duloxetine to relieve pain in patients with postherpetic Neuralgia(PHN).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostherpetic Neuralgia
CountriesChina
CollaboratorsBeijing Xiaotangshan Hospital, The First Hospital of Fangshan District,Beijing, Beijing Ditan Hospital, Hengshui People's Hospital

Timeline

N/ARecruitingOverdue
2026
First PostedMar 26, 2025
Enrollment StartApr 1, 2025
Primary CompletionApr 1, 2026
Study CompletionMay 1, 2026
TodayJul 1, 2026
Enrollment to primary: 1 yearPosted 1.3 years ago

Interventions

esketamine groupdrug

In the esketamine group, in addition to receiving the combination of pregabalin and duloxetine, patients will also undergo a single intravenous infusion of esketamine.

control groupdrug

receiving the combination of pregabalin and duloxetine